• 

  Preclinical evaluation of the PARP inhibitor BMN-673 for the treatment of ovarian clear cell cancer. 

  Wilkerson, PM; Dedes, KJ; Samartzis, EP; Dedes, I; Lambros, MB; Natrajan, R; Gauthier, A; Piscuoglio, S; Töpfer, C; Vukovic, V; Daley, F; Weigelt, B; Reis-Filho, JS (2017-01-24)

  PURPOSE: To determine if models of ovarian clear cell carcinomas (OCCCs) harbouring defects in homologous recombination (HR) DNA repair of double strand breaks (DSBs) are sensitive to cisplatin and/or PARP inhibition. ...
• 

  Variation of mutational burden in healthy human tissues suggests non-random strand segregation and allows measuring somatic mutation rates 

  Werner, B; Sottoriva, A
• 

  Splicing dysregulation as a driver of breast cancer 

  Read, A; Natrajan, R (2018-05-30)
• 

  Driver Oncogenes but Not as We Know Them: Targetable Fusion Genes in Breast Cancer. 

  Natrajan, R; Tutt, ANJ; Lord, CJ

  Two reports in this issue of Cancer Discovery outline how the genomic composition of tumors, including the presence of intragenic gene fusions, could inform the selection of treatment approaches in aggressive forms of the ...
• Noninvasive detection of HER2 amplification with plasma DNA digital PCR. 

  Gevensleben, H; Garcia-Murillas, I; Graeser, MK; Schiavon, G; Osin, P; Parton, M; Smith, IE; Ashworth, A; Turner, NC (2013-06)

  PURPOSE: Digital PCR is a highly accurate method of determining DNA concentration. We adapted digital PCR to determine the presence of oncogenic amplification through noninvasive analysis of circulating free plasma DNA and ...

View more